Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7;386(14):1377-1380.
doi: 10.1056/NEJMc2202542. Epub 2022 Mar 16.

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

Gili Regev-Yochay  1 , Tal Gonen  1 , Mayan Gilboa  1 , Michal Mandelboim  2 , Victoria Indenbaum  2 , Sharon Amit  3 , Lilac Meltzer  3 , Keren Asraf  3 , Carmit Cohen  3 , Ronen Fluss  3 , Asaf Biber  3 , Ital Nemet  2 , Limor Kliker  2 , Gili Joseph  3 , Ram Doolman  3 , Ella Mendelson  2 , Laurence S Freedman  3 , Dror Harats  3 , Yitshak Kreiss  3 , Yaniv Lustig  2
Affiliations

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

Gili Regev-Yochay et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Immunogenicity and Efficacy of a Fourth Dose of mRNA Vaccine.
Panel A shows IgG titers after three doses of BNT162b2 plus a fourth dose of a messenger RNA (mRNA) vaccine (either BNT162b2 or mRNA-1273). Panel B shows live-virus neutralization efficacy against different strains (Hu-1 [wild type], B.1.617.2 [delta], and B.1.1.529 [omicron]) at different time points. In Panels A and B, geometric mean titers are shown, and 𝙸 bars indicate the 95% confidence intervals; the dashed horizontal line indicates the cutoff for diagnostic positivity. Panel C shows the cumulative incidence of any severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among BNT162b2 and mRNA-1273 recipients and their matched controls. The dashed lines indicate 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021;385(24):e84-e84. - PMC - PubMed
    1. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474-1484. - PMC - PubMed
    1. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022;386:492-494. - PMC - PubMed
    1. Lustig Y, Gonen T, Melzer L, et al. Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose. December 21, 2021. (https://www.medrxiv.org/content/10.1101/2021.12.19.21268037v1). preprint. - PubMed

Supplementary concepts